Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TK1 | P04183 | 3/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | TK2 | O00142 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16378861 | 1.00 | LMNA (0.49) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL22765896 | 0.83 | TYMS (0.50) | — | |
| SCHEMBL19120634 | 0.79 | TK1 (0.50) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL6364684 | 0.79 | LMNA (0.44) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL2209009 | 0.79 | ADRB1 (0.47) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL19107434 | 0.79 | TK1 (0.50) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL22183560 | 0.78 | TK1 (0.44) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL4214653 | 0.78 | LMNA (0.49) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL4214655 | 0.78 | LMNA (0.49) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL25492408 | 0.78 | TK1 (0.44) | LMNASMN1; SMN2TK1ADRB1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146262-A1 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | MODERNATX, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4727914-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12595226-B2 | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4687992-A1 | LIPID-BASED NANOPARTICLE TARGETED AT ACTIVATED IMMUNE CELLS FOR THE EXPRESSION OF IMMUNE CELL INHIBITING MOLECULE AND USE THEREOF | OSE IMMUNOTHERAPEUTICS (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4687991-A1 | LIPID-BASED NANOPARTICLE TARGETED AT ACTIVATED IMMUNE CELLS FOR THE EXPRESSION OF IMMUNE CELL ENHANCING MOLECULE AND USE THEREOF | OSE IMMUNOTHERAPEUTICS (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4683666-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | ModernaTX, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4683667-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | ModernaTX, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4683665-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | ModernaTX, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260014281-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | MODERNATX, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014258-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | MODERNATX, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4096644-A1 | METHODS OF PREPARING LIPID NANOPARTICLES | Modernatx, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20220362372-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | PFIZER INC. | 2022-11-17 | — | — | US | disclosed |
| WO-2022204288-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| CN-115025247-A | Composition for encapsulating thrombopoietin mRNA and application thereof | 上海交通大学医学院 | 2022-09-09 | — | — | CN | disclosed |
| EP-4045647-A1 | NOVEL RNA APTAMER INTERVENES ESTROGEN RECEPTOR INTERACTION WITH COACTIVATOR MED1 TO OVERCOME BREAST CANCER METASTASIS | University of Cincinnati (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4039811-A1 | IMPROVED METHODS FOR PROCESSING DNA SUBSTRATES | Integrated DNA Technologies, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20220162672-A1 | METHODS FOR MULTIPLEX PCR | SWIFT BIOSCIENCES, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220106259-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2022-04-07 | — | — | US | disclosed |
| WO-2022032154-A2 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595226-B2 | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PCTP, PLTP | LMNA 266/4885SMN1; SMN2 567/4885TK1 2571/4885 |
| US-20260014258-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | ASGR1, LDLR, LPAR6 | LMNA 757/4885SMN1; SMN2 1622/4885TK1 1383/4885 |
| US-20220362372-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | RNASEH1, HAVCR2, HNRNPH3 | LMNA 772/4885SMN1; SMN2 2309/4885TK1 746/4885 |
| US-20260014281-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | ASGR1, LDLR, LPAR6 | LMNA 691/4885SMN1; SMN2 1495/4885TK1 1376/4885 |
| US-20260146262-A1 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | ELAVL1, IGF2BP2, FUS | LMNA 754/4885SMN1; SMN2 75/4885TK1 4646/4885 |
| US-20220106259-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | LMNA 712/4885SMN1; SMN2 1663/4885TK1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.